Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Search for FDA Guidance Documents

Search for FDA Guidance Documents

                        Search General and Cross-Cutting Topics Guidance Documents
          Advisory Committee Guidance Documents
          Import and Export Guidance Documents
          Cross-cutting Guidance Documents Home
          Regulatory Information
          Search for FDA Guidance Documents
          Draft Guidance for Industry:  Protein Efficiency Ratio (PER) Rat Bioassay Studies to Demonstrate that a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of ProteinSearch for FDA Guidance Documents GUIDANCE DOCUMENT
	Draft Guidance for Industry:  Protein Efficiency Ratio (PER) Rat Bioassay Studies to Demonstrate that a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein
					
		
		February 2023


	Download the  Draft  Guidance Document
	    
      	      		Read the Federal Register Notice 

    Draft

	  	    Not for implementation. Contains non-binding recommendations.
	  
	  
	Share
    Post
    Linkedin

    Email
    PrintDocket Number:
		    FDA-2022-D-2424
	    	    		    Issued by:
		    Guidance Issuing Office
          Center for Food Safety and Applied Nutrition


The Infant Formula Act of 1980 (Pub. L. 96-359) amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to include section 412 (21 U.S.C. 350a). In 1986, Congress amended section 412 of the FD&C Act to require FDA to establish quality factors for infant formula and stipulated that an infant formula would be considered adulterated if it does not meet the quality factor requirements.[1] On June 10, 2014, as part of the final rule, *Current Good Manufacturing Practices, Quality Control Procedures, Quality Factors, Notification Requirements, and Records and Reports, for Infant Formula* (Infant Formula Final Rule), FDA established requirements for quality factors for infant formulas (79 FR 33057), including the quality factor of sufficient biological quality of protein (21 CFR 106.96(e) and (f)).

An infant formula must meet the quality factor of sufficient biological quality of protein (21 CFR 106.96(e)).  Specifically, 21 CFR 106.96(f) describes how an infant formula manufacturer must demonstrate that a formula meets this quality factor:

A manufacturer of an infant formula that is not an eligible infant formula shall demonstrate that a formula meets the quality factor of sufficient biological quality of protein by establishing the biological quality of the protein in the infant formula when fed as the sole source of nutrition using an appropriate modification of the Protein Efficiency Ratio (PER) rat bioassay described in the “Official Methods of Analysis of AOAC International,” 18th ed., sections 45.3.04 and 45.3.05, “AOAC Official Method 960.48 Protein Efficiency Ratio Rat Bioassay,” which is incorporated by reference at § 106.160 (see Appendix 1).  The PER rat bioassay shall be conducted on a formula and the results evaluated prior to the initiation of a growth monitoring study of the formula that is required under 21 CFR 106.96(b).

Conducting a PER study in an animal model[2] permits a determination of a formula’s protein quality before infants are exposed to the formula.[3] This approach ensures that infants will not be fed a formula with inadequate or biologically unavailable protein.[4]

We have developed this guidance to help manufacturers and laboratories in the design, conduct, evaluation, and reporting of PER studies.  The guidance is intended to explain how the PER study can be used to provide assurance that a new infant formula meets the quality factor of sufficient biological quality of protein in the infant formula when fed as the sole source of nutrition using appropriate modifications of AOAC Official Method 960.48 (the AOAC Method; Reference 1) (see 21 CFR 106.96(f)).

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

Download the Draft Guidance

[1] See Anti-Drug Abuse Act of 1986, Pub. L. 99-570, § 4014.

[2] We support the principles of the “3Rs” to reduce, refine and replace animal use in testing when feasible.  We encourage sponsors to consult with us if they wish to use a non-animal testing method they believe is suitable, adequate, and validated to demonstrate that the formula supports the quality factor for the biological quality of the protein as described in 21 CFR 106.96(g)(3).  We support alternative methods by exemption in 21 CFR 106.96(f) which allows the manufacturer to request an exemption and provide certain required assurances described in 21 CFR 106.96(g).  The applicability of this exemption is not the subject of this guidance.

[3] Current Good Manufacturing Practices, Quality Control Procedures, Quality Factors, Notification Requirements, and Records and Reports, for Infant Formula, Interim Final Rule, 79 FR 7934, at 8023, Feb. 10, 2014.

[4] 79 FR at 8023.

Related Resources

Final rule: Current Good Manufacturing Practices, Quality Control Procedures, Quality Factors, Notification Requirements, and Records and Reports, for Infant Formula
	Constituent Update: FDA Provides Guidance on Protein Quality Studies for Infant Formula
	Infant Formula Guidance Documents & Regulatory InformationSubmit Comments
	   		  			    		Submit Comments Online
					You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
						If unable to submit comments online, please mail written comments to:
						Dockets Management
							Food and Drug Administration
							5630 Fishers Lane, Rm 1061
							Rockville, MD 20852
						All written comments should be identified with this document's docket number: FDA-2022-D-2424.

                                                                                  Content current as of:
      02/24/2023
         
                  
Regulated Product(s)
		 Food & Beverages
			  			     			  						              
			
			
			
			
			
						  Infant Formula & FoodsSearch for FDA Guidance Documents

        Search for FDA Guidance Documents

          
                        Search General and Cross-Cutting Topics Guidance Documents
          Advisory Committee Guidance Documents
          Import and Export Guidance Documents
          Cross-cutting Guidance Documents
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop